Catherine Shu, MD

Dr. Catherine Shu, a leading expert in thoracic oncology at Columbia University, discusses the promising results of tepotinib in treating non-small cell lung cancer with MET exon 14 skipping mutations. She delves into the phase 2 VISION trial, highlighting impressive efficacy, early response rates, and long-term follow-up data. Dr. Shu emphasizes the need for next-generation sequencing in early detection and shares insights on managing side effects, ensuring patient safety throughout treatment. It's a deep dive into targeted therapies that could reshape cancer care.